Skip to main content
Clinical Trials/NCT04189562
NCT04189562
Unknown
N/A

A Text Messaging (SMS) Intervention to Improve Adherence to Stimulant Medications in Children With ADHD

Massachusetts General Hospital1 site in 1 country300 target enrollmentFebruary 22, 2017

Overview

Phase
N/A
Intervention
Not specified
Conditions
Attention Deficit/Hyperactivity Disorder
Sponsor
Massachusetts General Hospital
Enrollment
300
Locations
1
Primary Endpoint
Adherence to Stimulants
Last Updated
3 years ago

Overview

Brief Summary

This study will assess the efficacy of the text messaging (SMS-based) disease management intervention for children with Attention Deficit/Hyperactivity Disorder (ADHD) using the timeliness of stimulant prescription renewals over a 9-month period.

Parents of participants in the study will receive customized text messages once a day, Sunday through Friday, for a duration of 9 months. The text messages will include reminders to adhere to the individualized medication regimen, reminders to call their child's clinician for a prescription refill followed by reminders to pick up medication from the pharmacy, and educational reminders about ADHD and its treatment.

Registry
clinicaltrials.gov
Start Date
February 22, 2017
End Date
June 2023
Last Updated
3 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Joseph Biederman, MD

Chief of the Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD

Massachusetts General Hospital

Eligibility Criteria

Inclusion Criteria

  • Children 6-12 years of age of both sexes and their parent
  • A diagnosis of ICD-10 or DSM 5 diagnosis of Attention Deficit/Hyperactivity Disorder including the following ICD codes (F90 Attention-deficit hyperactivity disorders; F90.0 Attention-deficit hyperactivity disorder, predominantly inattentive type; F90.1 Attention- deficit hyperactivity disorder, predominantly hyperactive type; F90.2 Attention-deficit hyperactivity disorder, combined type;F90.8 Attention-deficit hyperactivity disorder, other type; F90.9 Attention-deficit hyperactivity disorder, unspecified type) and/or the following DSM 5 diagnoses (314.01, F90.2 Attention-deficit/hyperactivity disorder, combined presentation; 314.01, F90.1 Attention-deficit/hyperactivity disorder, predominantly hyperactive/impulsive presentation;314.00, F90.0 Attention- deficit/hyperactivity disorder, predominantly inattentive presentation)
  • Starting or currently on stimulant medication including (Amphetamine/Dextroamphetamine (Adderall);Dextroamphetamine (Dexedrine, ProCentra, Zenzedi, Adderall XR); Dexmethylphenidate (Focalin, Focalin XR); Methylphenidate (Ritalin, Ritalin SR, Metadate ER, Methylin ER, Concerta, Daytrana, Metadate CD, Quillivant XR, Ritalin LA); Amphetamine sulfate (Evekeo); Lisdexamfetamine (Vyvanse))
  • Proficient in English
  • Has a cellular phone with text messaging capabilities and is interested in and willing to receive free of charge text messages

Exclusion Criteria

  • Investigator and his/her immediate family
  • Unwilling/unable to comply with study procedures

Outcomes

Primary Outcomes

Adherence to Stimulants

Time Frame: 9 months

Adherence will be analyzed using the timeliness of stimulant medication prescription renewals over the 9 month period as documented in the participants medical record.

Study Sites (1)

Loading locations...

Similar Trials